Merck & Co.

AWARDS

NEWS

Merck’s Experimental Pneumonia Vaccine Hits the Mark in Two Phase III Studies

Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients.

June 22, 2020

2 min read

Alex Keown

Policy

FDA Action Alert: Karyopharm, Zogenix, Chiasma, Heron, Intercept and Merck

Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.

June 19, 2020

3 min read

Mark Terry

FDA

FDA Approves Second Biomarker-Specific Indication for Merck’s Keytruda

This is the second such biomarker-specific approval for Keytruda. The first biomarker-specific approval came in 2017.

June 17, 2020

2 min read

Alex Keown

BioCapital

Clinical Catch-Up: June 8-12

It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

June 12, 2020

12 min read

Mark Terry

Drug Development

Biopharma Update on the Novel Coronavirus: June 12

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.

June 11, 2020

4 min read

BioSpace Editorial Staff

Drug Development

Merck’s Keytruda Fails to Hit Mark in First-Line Bladder Cancer Treatment Trial

KEYNOTE-361 is evaluating Keytruda alone and in combination with chemotherapy compared to chemotherapy alone, the current standard of care, for first-line treatment of advanced or metastatic urothelial carcinoma.

June 10, 2020

3 min read

Mark Terry